Legionnaires' Disease

1. Clinical Overview

Summary

Legionnaires' disease is a severe, potentially life-threatening atypical pneumonia caused by the Gram-negative bacterium Legionella pneumophila. This waterborne pathogen is transmitted exclusively through inhalation of contaminated aerosols from water sources such as cooling towers, air conditioning systems, hot tubs, and showers—not through person-to-person contact. [1,2]

The disease represents 2-9% of community-acquired pneumonia (CAP) cases but accounts for a disproportionately high number of severe pneumonia cases requiring ICU admission. [3,4] Mortality ranges from 5-10% in community-acquired cases to 15-30% in ICU patients, with untreated cases approaching 80% mortality. [5,6]

Classic clinical triad: Severe pneumonia + gastrointestinal symptoms (diarrhea 25-50%) + hyponatremia (30-60%). [7,8] The diagnosis requires high clinical suspicion as standard beta-lactam antibiotics are completely ineffective due to the organism's intracellular location. [9]

First-line treatment: Fluoroquinolones (levofloxacin) or macrolides (azithromycin) for 7-14 days depending on severity. [10,11] Legionnaires' disease is a notifiable disease requiring public health investigation to identify and remediate environmental sources and prevent outbreaks. [12]

Key Facts

• Organism: Legionella pneumophila (Gram-negative, facultative intracellular pathogen)
• Serogroups: Serogroup 1 accounts for 70-90% of clinical cases [13]
• Transmission: Inhalation of aerosolized water droplets (1-5 μm) from contaminated sources
• Incubation Period: 2-10 days (median 6-7 days) [14]
• Sources: Cooling towers (outbreak source), hot tubs, showers, decorative fountains, hospital water systems
• Classic Features: Pneumonia + Diarrhea + Confusion + Hyponatremia + Relative bradycardia
• Laboratory Clues: Hyponatremia (30-60%), lymphopenia (40-70%), elevated transaminases (50%)
• Diagnosis: Urinary antigen test (detects L. pneumophila serogroup 1 only), PCR (all serogroups), culture on BCYE agar
• Treatment: Levofloxacin 500mg BD IV or Azithromycin 500mg OD IV for 7-14 days
• Critical Point: Beta-lactams (penicillins, cephalosporins) are INEFFECTIVE—Legionella is intracellular

Clinical Pearls

"Hyponatremia + Pneumonia = Think Legionella": Serum sodium less than 130 mmol/L occurs in 30-60% of cases and is a powerful diagnostic clue. The combination of severe pneumonia with hyponatremia should immediately raise suspicion for Legionnaires' disease. [15,16]

"GI + CNS Symptoms in Pneumonia = Atypical": Unlike pneumococcal pneumonia, Legionella commonly causes diarrhea (25-50%), nausea/vomiting (30-40%), and confusion (30%). These "extrapulmonary" features distinguish it from typical bacterial pneumonia. [17,18]

"Penicillins Don't Work—Ever": Legionella is a facultative intracellular pathogen that replicates within alveolar macrophages. Beta-lactams (amoxicillin, co-amoxiclav, cephalosporins) cannot achieve adequate intracellular concentrations. Use fluoroquinolones or macrolides. [19,20]

"Urinary Antigen Misses 20-30%": The rapid urinary antigen test detects only L. pneumophila serogroup 1. In endemic areas or outbreaks with non-serogroup 1 strains, send respiratory PCR to avoid false negatives. [21,22]

"Always Notify Public Health": Legionnaires' disease is legally notifiable. Environmental investigation can identify contaminated water systems and prevent additional cases—especially critical in healthcare facilities and hotels. [23]

---

2. Epidemiology

Global Burden

Legionnaires' disease is increasingly recognized worldwide with rising incidence over the past two decades. [24,25] The increase reflects improved diagnostics (urinary antigen testing), heightened clinical awareness, population aging, and potentially environmental factors including climate change affecting water system temperatures. [26]

Incidence

United States:

• Reported cases increased from 1,110 (2000) to 10,081 (2021)—a 9-fold increase over 21 years [27]
• Estimated incidence: 3.3 per 100,000 population (2021)
• True incidence likely 2-3× higher due to underdiagnosis [28]

Europe:

• 10,000-12,000 reported cases annually (European Centre for Disease Prevention and Control)
• Incidence: 1.2-2.2 per 100,000 population [29]
• Higher rates in Mediterranean countries (travel-associated cases)

United Kingdom:

• 300-600 cases reported annually
• Accounts for 2-3% of community-acquired pneumonia [30]

Outbreak vs Sporadic Cases:

• 90-95% of cases are sporadic
• 5-10% occur in recognized outbreaks (often linked to cooling towers, hotels, hospitals) [31]

Demographics

Age Distribution:

• Peak incidence: 50-79 years
• Median age: 65 years [32]
• Rare in children (less than 1% of cases)
• Age-related risk: Incidence increases ~20-fold from age 40 to 80 [33]

Sex Distribution:

• Male:Female ratio = 2.5-3:1 [34,35]
• Higher occupational exposure in males may contribute
• Biological factors (smoking rates, comorbidities) also play a role

Seasonality:

• Peak incidence: July-October in Northern Hemisphere (summer/early autumn) [36]
• Correlates with warmer water temperatures (25-45°C optimal for Legionella growth)
• Air conditioning use increases exposure to cooling towers

Risk Factors

Host Risk Factors

Environmental/Exposure Risk Factors

Water Temperature and Legionella Growth

Legionella thrives in specific temperature ranges: [51]

• Below 20°C: Dormant (minimal growth)
• 20-25°C: Slow growth begins
• 25-45°C: Optimal growth range
• 35-37°C: Peak growth rate
• Above 50°C: Declining viability
• Above 60°C: Rapid death (within minutes)

This temperature dependence explains:

• Seasonal peaks in summer/autumn
• Risk from warm water systems (hot tubs, showers)
• Prevention strategies (thermal disinfection > 60°C, cold water less than 20°C)

---

3. Pathophysiology

Microbiology

Taxonomy:

• Genus: Legionella (> 60 species identified)
• Species: Legionella pneumophila (causes 90% of human disease) [52]
• Serogroups: 16 serogroups of L. pneumophila
  • "Serogroup 1: 70-90% of clinical cases"
  • "Serogroups 2-15: 10-30% of cases"

Other pathogenic species (5-10% of cases):

• L. longbeachae (Australia/New Zealand—associated with potting soil)
• L. micdadei, L. bozemanii, L. dumoffii

Bacterial Characteristics:

• Gram-negative rod (0.3-0.9 μm × 2-20 μm)
• Stains poorly on Gram stain—requires silver stain (Dieterle) for visualization in tissue
• Fastidious growth requirements: Cannot grow on standard blood agar
• Requires BCYE (buffered charcoal yeast extract) agar with L-cysteine and iron supplementation
• Culture requires 3-5 days (up to 10 days for some strains)
• Facultative intracellular pathogen (replicates within protozoa and human macrophages)

Environmental Reservoir

Natural Habitat: Legionella is ubiquitous in freshwater environments worldwide: [53]

• Rivers, lakes, streams (low concentrations)
• Soil and potting mix (especially L. longbeachae)
• Biofilms (symbiotic relationship with amoebae and other protozoa)

Amplification in Engineered Water Systems: [54,55]

1. Biofilm formation: Legionella colonizes pipe surfaces, water heaters, cooling towers
2. Amoeba hosts: Replicates inside Acanthamoeba, Naegleria, Hartmannella species
   • Amoebae protect Legionella from chlorine disinfection
   • Enhance Legionella virulence and environmental survival
3. Temperature stagnation: Warm water (25-45°C) promotes exponential growth
4. Nutrient availability: Scale, sediment, organic matter support biofilm growth

High-Risk Water Systems:

• Cooling towers and evaporative condensers
• Hot water storage tanks and distribution systems
• Whirlpool spas and hot tubs
• Decorative fountains and water features
• Respiratory therapy equipment, humidifiers
• Dental unit waterlines
• Premise plumbing in large buildings (hotels, hospitals, care homes)

Transmission

Route of Infection: Inhalation of contaminated aerosols [56,57]

1. Aerosolization: Water droplets (1-5 μm diameter) generated by:

   • Cooling tower drift
   • Shower heads and tap aerators
   • Hot tub/spa jets
   • Decorative fountains
   • Respiratory nebulizers

2. Inhalation: Droplets small enough to reach alveoli (> 5 μm droplets are trapped in upper airways)

3. NOT transmitted:

   • Person-to-person transmission (no documented cases)
   • Ingestion of contaminated water (unless aspirated)
   • Direct contact with water (requires aerosolization)

Inoculum: Infectious dose unknown, but estimated to be low (less than 1,000 organisms may cause disease in susceptible hosts)

Molecular Pathogenesis

Entry and Phagocytosis

After inhalation, Legionella encounters alveolar macrophages: [58,59]

1. Attachment: Surface proteins (Mip, Hsp60) bind macrophage receptors (CR1, CR3, Fcγ receptors)
2. Phagocytosis: Legionella induces uptake via coiling phagocytosis or conventional phagocytosis
3. Phagosome formation: Bacterium resides in early phagosome

Normal host response: Phagosome matures → phagolysosome → bacterial killing

Legionella strategy: Block phagosome-lysosome fusion and create a replicative niche

Dot/Icm Type IV Secretion System (T4SS)

The Dot/Icm T4SS is the central virulence mechanism of Legionella: [60,61]

• 26 Dot/Icm proteins form a molecular syringe spanning bacterial membranes
• Injects > 300 effector proteins into host cell cytoplasm
• Effectors manipulate host cell processes:
  1. Inhibit phagosome-lysosome fusion
  2. Recruit ER-derived vesicles to the phagosome
  3. Block apoptosis (host cell programmed death)
  4. Inhibit innate immune signaling

Key effector functions: [62,63]

• SidM/DrrA: Activates Rab1 GTPase → recruits ER vesicles to phagosome
• LepB: Rab1 GAP (turns off Rab1 after vesicle recruitment)
• SdhA: Maintains phagosome integrity
• LegK1: Phosphorylates caspases → prevents apoptosis
• LnaB/SidL: Inhibits NF-κB signaling → blocks inflammatory cytokines

Legionella-Containing Vacuole (LCV)

Within 15-30 minutes post-infection, the Legionella phagosome transforms into the LCV: [64,65]

Characteristics:

• Decorated with ER markers (ribosomes, ER chaperones)
• Avoids lysosomal markers (LAMP1, cathepsins)
• Intercepts ER-to-Golgi vesicular traffic
• Acidic pH (5.0-6.0) but permissive for replication

Nutrient acquisition:

• LCV communicates with host ER → amino acids
• Autophagy machinery recruited (but not degradative) → amino acids from protein turnover
• Iron acquisition via siderophores and heme utilization
• Fatty acids from host lipid droplets

Replication and Spread

Intracellular Growth: [66]

• Generation time: 2-4 hours
• 20-100 bacteria per cell before lysis
• Host cell viability maintained until late stages (24-48 hours)

Exit and Re-infection:

1. Bacterial density sensing (quorum sensing) triggers transition to transmissive phase
2. Upregulation of flagellar motility, cytotoxicity
3. Cell lysis releases bacteria
4. Flagellated bacteria invade adjacent macrophages
5. Cycle repeats → necrotizing pneumonia

Host Immune Response

Innate Immunity: [67,68]

• Neutrophils: Limited efficacy (Legionella survives in neutrophils)
• Alveolar macrophages: Primary host cell (also site of replication—paradox)
• Inflammasome activation: NLRC4, NAIP5 detect flagellin → IL-1β, IL-18 release
• Cytokine storm: TNF-α, IL-6, IL-8 → systemic inflammation, fever

Adaptive Immunity:

• CD4+ T cells: Critical for bacterial clearance (IFN-γ activates macrophages)
• Antibodies: Provide some protection, but cell-mediated immunity is essential
• Immunosuppressed patients (transplant, HIV, corticosteroids) at highest risk

Systemic Effects

Hyponatremia (30-60% of cases)

Mechanisms: [69,70]

1. SIADH (Syndrome of Inappropriate ADH):
   • Pneumonia-induced ADH release
   • High urine osmolality, low serum osmolality
   • Urine sodium > 20 mmol/L
2. Direct renal tubular effects:
   • Endotoxin and cytokine effects on sodium transport
3. Gastrointestinal losses:
   • Diarrhea/vomiting → volume depletion → ADH release
4. Fever-induced fluid shifts

Diagnostic Utility:

• Sodium less than 130 mmol/L: Sensitivity 40-60%, Specificity 70-80% for Legionella vs other CAP [71]
• Combined with pneumonia + diarrhea: positive likelihood ratio 5-8

Other Systemic Manifestations

Hepatic:

• Elevated transaminases (AST/ALT 2-5× ULN) in 50% [72]
• Usually mild; rarely clinically significant hepatitis

Renal:

• Acute kidney injury (AKI) in 15-30% of severe cases [73]
• Mechanisms: Sepsis, rhabdomyolysis, tubular injury

Neurological:

• Encephalopathy/confusion (30%)
• Headache (40-50%)
• Cerebellar dysfunction (rare): ataxia, dysarthria
• Mechanism: Cytokine-mediated, endotoxin effects (Legionella does not invade CNS)

Cardiac:

• Relative bradycardia ("pulse-temperature dissociation"): fever > 39°C with pulse less than 100 bpm [74]
• Myocarditis (rare)

Hematologic:

• Lymphopenia (40-70%): CD4+ and CD8+ T cell depletion [75]
• Thrombocytopenia (mild, 20-30%)

---

4. Clinical Presentation

Symptom Spectrum

Legionnaires' disease presents with heterogeneous severity ranging from mild pneumonia to fulminant respiratory failure. [76,77]

Timeline

Incubation Period: 2-10 days (median 6-7 days) after exposure [78]

Prodrome (Days 1-2):

• Malaise, fatigue
• Myalgia (50-70%)
• Headache (40-50%)
• Low-grade fever

Pneumonia Phase (Days 3-7):

• High fever (> 39°C in 80-95%)
• Cough (initially dry, may become productive)
• Dyspnea (progressive)
• Pleuritic chest pain (30%)
• Gastrointestinal symptoms
• Neurological symptoms

Cardinal Features

Respiratory Symptoms

Gastrointestinal Symptoms (Highly Characteristic)

Clinical Pearl: The combination of pneumonia + diarrhea is rare in typical bacterial pneumonia and should prompt testing for Legionella (also consider atypical pathogens, viral pneumonia).

Neurological Symptoms

Physical Examination Findings

Vital Signs

Temperature:

• High fever (39-40.5°C) in 90-95%
• Occasionally low-grade or absent in immunosuppressed patients

Pulse:

• Tachycardia in most patients
• Relative bradycardia (pulse-temperature dissociation): 15-30% of cases [85]
  • Fever > 39°C with pulse less than 100 bpm
  • Suggests Legionella, typhoid, drug fever (not specific)

Respiratory Rate:

• Tachypnea (> 20 breaths/min) in 70-90%
• Respiratory distress (accessory muscle use, nasal flaring) in severe cases

Blood Pressure:

• Normotensive in mild-moderate cases
• Hypotension/shock in 10-20% (poor prognostic sign) [86]

Oxygen Saturation:

• Hypoxemia (SpO2 less than 92% on room air) in 50-70%
• Severe hypoxemia (SpO2 less than 85%) in 20-30% of hospitalized cases

Respiratory Examination

Inspection:

• Respiratory distress in moderate-severe cases
• Cyanosis if severe hypoxemia

Palpation:

• Reduced chest expansion on affected side (if lobar consolidation)

Percussion:

• Dullness over consolidated areas
• Stony dull if pleural effusion

Auscultation:

• Crackles (rales): Fine inspiratory crackles over affected lobes (80-90%)
• Bronchial breath sounds: In areas of dense consolidation (40-60%)
• Reduced breath sounds: Especially if effusion present (30-40%)
• Pleural rub: Occasional if pleural inflammation

Extrapulmonary Examination

Neurological:

• Confusion, disorientation (assess GCS/AMTS)
• Rare: cerebellar signs (ataxia, dysdiadochokinesia)

Cardiovascular:

• Tachycardia (or relative bradycardia as above)
• Hypotension in severe sepsis

Abdominal:

• Hepatomegaly (mild, 10-20%)
• Diffuse tenderness if GI symptoms prominent

Clinical Variants

Pontiac Fever (Non-Pneumonic Legionellosis)

Characteristics: [87,88]

• Acute febrile illness without pneumonia
• Caused by same Legionella species, but no pulmonary infiltrates
• Incubation: 24-48 hours (shorter than Legionnaires' disease)
• Attack rate: Very high (> 90% of exposed individuals in outbreaks) vs less than 5% for Legionnaires' disease
• Symptoms: Fever, chills, myalgia, headache, malaise
• Duration: Self-limited (2-5 days); full recovery without antibiotics
• Mechanism: Unclear (possibly immune response to inhaled endotoxin without infection, or aborted infection)

Clinical Significance:

• Pontiac fever outbreaks indicate heavy environmental Legionella contamination
• Signals high risk for concurrent Legionnaires' disease cases
• Public health investigation mandatory

Nosocomial Legionnaires' Disease

Epidemiology: [89]

• 1-4% of hospital-acquired pneumonia
• Onset ≥48 hours after admission or within 10 days post-discharge
• Higher mortality (15-30%) than community-acquired LD

Risk Factors:

• Immunosuppression (transplant patients particularly vulnerable)
• Prolonged hospitalization
• ICU admission
• Mechanical ventilation
• Aspiration risk

Source: Hospital water distribution systems (especially older buildings with complex plumbing)

Prevention: Water management programs, thermal disinfection, copper-silver ionization

Legionnaires' Disease in Immunocompromised Hosts

Transplant Recipients: [90]

• Incidence: 0.5-6% of solid organ transplant recipients
• Median onset: 6-12 months post-transplant
• Mortality: 25-50% (higher than general population)
• Presentation: Often fulminant; higher rate of disseminated disease

HIV/AIDS:

• Risk increases when CD4 less than 100 cells/μL
• Presentation similar to other patients (no specific differences)

Hematologic Malignancy/Chemotherapy:

• Neutropenia increases risk
• May have atypical presentation (lower fever, less pulmonary infiltrate)

Comparison with Other Pneumonias

---

5. Investigations

First-Line Investigations

Urinary Antigen Test (UAT)

Methodology: [91,92]

• Immunochromatographic lateral flow assay or enzyme immunoassay (EIA)
• Detects lipopolysaccharide (LPS) antigen of L. pneumophila serogroup 1 in urine
• Results available in 15-30 minutes (rapid test) or 1-3 hours (EIA)

Performance Characteristics: [93,94]

• Sensitivity: 70-90% for L. pneumophila serogroup 1 pneumonia
  • Lower sensitivity in mild disease (50-60%)
  • Higher sensitivity in severe disease (80-95%)
• Specificity: 95-99% (very high)
• Positive Predictive Value: Depends on prevalence; high in appropriate clinical context
• Negative Predictive Value: 70-85% (cannot rule out Legionella)

Advantages:

• Rapid (point-of-care)
• Non-invasive (urine sample)
• High specificity (few false positives)
• Remains positive for days-weeks (even after antibiotic initiation)
• Not affected by prior antibiotic therapy

Limitations: [95,96]

• Only detects L. pneumophila serogroup 1 (misses 10-30% of cases)
  • Does NOT detect serogroups 2-15
  • Does NOT detect other Legionella species (L. longbeachae, L. micdadei, etc.)
• Sensitivity lower in mild disease or early infection
• Rare false positives (cross-reactivity with other bacteria—very rare)

Clinical Recommendation: [97]

• Send UAT for all patients with moderate-severe CAP
• If negative but high clinical suspicion → send respiratory PCR and/or culture
• Positive UAT = definite Legionnaires' disease (initiate treatment, notify public health)

Blood Tests

Complete Blood Count:

• White cell count: Variable (normal in 20%, elevated in 60%, leukopenia in 20%)
• Lymphopenia: 40-70% of cases (absolute lymphocyte count less than 1.0 × 10⁹/L) [98]
• Thrombocytopenia: Mild, 20-30%

Renal Function:

• Hyponatremia (Na less than 130 mmol/L): 30-60% of cases [99,100]
  • Most specific laboratory finding for Legionella
  • "Median sodium: 128-132 mmol/L in Legionnaires' disease vs 135-138 mmol/L in pneumococcal pneumonia"
• Acute kidney injury (elevated creatinine): 15-30% of hospitalized cases

Liver Function Tests:

• Elevated transaminases (AST/ALT): 50-70%
  • Usually 2-5× upper limit of normal
  • Rarely progresses to clinical hepatitis

C-Reactive Protein (CRP):

• Markedly elevated (> 100-300 mg/L in most cases)
• Non-specific but indicates severe inflammation

Procalcitonin:

• Elevated in bacterial pneumonia (> 0.5 ng/mL)
• Cannot distinguish Legionella from other bacterial pneumonias

Arterial Blood Gas (if hypoxemic):

• PaO2 less than 60 mmHg (hypoxemia)
• PaO2/FiO2 less than 200 mmHg (severe respiratory failure/ARDS)
• Respiratory alkalosis (early) or acidosis (late sepsis)

Chest X-Ray (CXR)

Common Patterns: [101,102]

• Lobar consolidation: 40-60%
  • Often unilateral
  • Lower lobe predominance
• Patchy/multilobar consolidation: 30-40%
• Interstitial/reticulonodular infiltrates: 10-20%
• Bilateral involvement: 30-50% (poor prognostic sign)

Associated Findings:

• Pleural effusion: 30-60% (usually small; occasionally moderate-large)
• Cavitation: Rare (5-10%); more common in immunosuppressed patients
• Lymphadenopathy: Uncommon on CXR (may be seen on CT)

Radiographic Progression: [103]

• 50% of patients show radiographic worsening in first 48-72 hours despite appropriate antibiotics
• Clinical improvement often precedes radiographic improvement
• Complete radiographic resolution: 2-8 weeks (slower than clinical resolution)

CT Chest (not routine, but performed in some cases):

• Consolidation (often with air bronchograms)
• Ground-glass opacities
• Pleural effusions (better detected than on CXR)
• Lymphadenopathy (mediastinal/hilar)

Microbiological Confirmation

Legionella PCR (Respiratory Sample)

Sample Types: [104]

• Sputum (expectorated or induced)
• Bronchoalveolar lavage (BAL)
• Tracheal aspirate (if intubated)

Methodology:

• Real-time PCR targeting Legionella-specific genes (5S rRNA, mip, wzm)
• Multiplex respiratory PCR panels (detects Legionella + other respiratory pathogens)

Performance:

• Sensitivity: 80-95% (higher than UAT for non-serogroup 1 and other species) [105]
• Specificity: 95-99%
• Detects all Legionella species and serogroups (major advantage over UAT)
• Results in 4-24 hours (depending on lab turnaround)

Advantages:

• Detects all Legionella (not just L. pneumophila sg1)
• High sensitivity
• Faster than culture

Limitations:

• Requires respiratory sample (not always obtainable)
• Cannot provide isolate for antibiotic susceptibility testing or epidemiological typing
• Rare false positives (colonization vs infection; contamination)

Culture on BCYE Agar

Methodology: [106,107]

• Respiratory sample (sputum, BAL, lung tissue)
• Inoculated onto buffered charcoal yeast extract (BCYE) agar supplemented with:
  • L-cysteine (required for Legionella growth)
  • Iron
  • α-ketoglutarate
• Incubated at 35°C in humidified atmosphere for 3-10 days

Appearance:

• Colonies: Small, glistening, convex
• Color: Gray-white to light blue
• Morphology: "Cut-glass" appearance under magnification

Performance:

• Sensitivity: 50-80% (lower than PCR/UAT because Legionella is fastidious)
• Specificity: 100% (gold standard)
• Time to result: 3-10 days (too slow for acute management)

Advantages:

• Provides isolate for:
  • Antibiotic susceptibility testing (if treatment failure)
  • Molecular typing (outbreak investigation, source attribution)
• Definitive diagnosis

Limitations:

• Slow (not useful for acute diagnosis)
• Requires specialized media (not all labs perform)
• Lower sensitivity than PCR
• Positive only if viable organisms present (may be negative after antibiotics started)

Serology (Antibody Testing)

Methodology: [108]

• Indirect fluorescent antibody (IFA) or ELISA
• Detects IgM and IgG antibodies to Legionella
• Requires paired sera (acute and convalescent, 3-6 weeks apart)

Diagnostic Criteria:

• 4-fold rise in antibody titer between acute and convalescent samples
• Single titer ≥1:128 (suggestive but not diagnostic)

Performance:

• Sensitivity: 60-80% (retrospective only)
• Specificity: 90-95%

Limitations:

• Retrospective diagnosis only (not useful for acute management)
• Requires convalescent sample (3-6 weeks later)
• Antibody rise may be absent in immunosuppressed patients
• Cannot distinguish between species/serogroups
• Cross-reactivity with other bacteria

Current Role: Very limited; primarily for seroprevalence studies and outbreak investigations when other tests unavailable

Diagnostic Algorithm

All patients with moderate-severe CAP:

1. Urinary Legionella antigen (rapid, first-line)
2. Blood cultures (rule out other bacteria)
3. Sputum culture (if obtainable; sent for routine bacteria + Legionella culture on BCYE)

If UAT positive:

• Diagnosis confirmed (L. pneumophila serogroup 1)
• Initiate specific treatment (fluoroquinolone or macrolide)
• Notify public health

If UAT negative but high clinical suspicion (pneumonia + diarrhea + hyponatremia + travel/exposure history):

• Send respiratory PCR (sputum, BAL)
• Consider Legionella culture on BCYE agar
• Empiric treatment with Legionella-active antibiotic (levofloxacin or azithromycin)

High suspicion criteria: [109]

• Pneumonia + ≥2 of:
  • Diarrhea
  • Hyponatremia (Na less than 130)
  • Elevated LFTs (AST/ALT > 2× ULN)
  • Lymphopenia
  • Failure to improve on beta-lactam antibiotics
  • Travel/outbreak exposure

---

6. Management

Antibiotic Therapy

Critical Principle: Legionella is a facultative intracellular pathogen that replicates within macrophages. Effective antibiotics must achieve high intracellular concentrations. [110,111]

First-Line Antibiotics

Fluoroquinolones (Preferred for severe disease): [112,113]

Macrolides (Alternative, especially for milder disease): [114,115]

Comparative Efficacy: Fluoroquinolones vs Macrolides

Meta-analysis Data: [116,117]

• Kato et al. (2021): Meta-analysis of 11 studies (1,329 patients)

  • "Mortality: Fluoroquinolones 7.2% vs Macrolides 10.8% (OR 0.64, 95% CI 0.44-0.94; p=0.02)"
  • Fluoroquinolones associated with lower mortality
  • Particularly beneficial in severe disease

• Jasper et al. (2021): Systematic review

  • No difference in mortality in mild-moderate disease
  • Trend toward lower mortality with fluoroquinolones in ICU patients

Clinical Recommendation: [118,119]

• Severe disease (ICU, respiratory failure): Levofloxacin preferred
• Mild-moderate disease: Either levofloxacin or azithromycin acceptable
• Monotherapy is standard; combination therapy not routinely recommended

Combination Therapy (Controversial)

Rationale:

• Synergistic activity in vitro
• Potentially faster bacterial clearance in severe disease

Regimens:

• Fluoroquinolone + Macrolide
• Fluoroquinolone + Rifampin (enhances intracellular killing)

Evidence: [120]

• Limited RCT data
• Some observational studies suggest benefit in ICU patients
• Other studies show no benefit

Current Recommendation:

• Not routinely recommended
• Consider in life-threatening disease (septic shock, severe ARDS) on individualized basis
• No strong evidence to support routine use

INEFFECTIVE Antibiotics (Do NOT Use)

Beta-lactams: [121]

• Penicillins (amoxicillin, ampicillin, piperacillin)
• Cephalosporins (ceftriaxone, cefotaxime, cefuroxime)
• Carbapenems (meropenem, imipenem)
• Reason: Poor intracellular penetration; Legionella is protected within macrophages

Aminoglycosides:

• Gentamicin, amikacin
• Reason: Poor intracellular penetration

Glycopeptides:

• Vancomycin
• Reason: Gram-negative bacteria; no activity

Clinical Pearl: If a patient with CAP fails to improve on beta-lactam monotherapy (e.g., ceftriaxone), consider Legionella and add/switch to fluoroquinolone or macrolide.

Antibiotic Switching and Duration

IV to Oral Switch: [122] When patient:

• Afebrile for 24-48 hours
• Hemodynamically stable
• Improving respiratory symptoms
• Tolerating oral intake

Duration:

• Mild-moderate disease: 7-10 days
• Severe disease/ICU: 10-14 days
• Immunocompromised hosts: 14-21 days (higher relapse risk)
• Azithromycin: 5-7 days often sufficient (long half-life, intracellular accumulation)

Clinical Endpoint:

• Clinical improvement (resolution of fever, improved oxygenation, symptom improvement)
• NOT radiographic resolution (CXR lags behind clinical improvement by weeks)

Supportive Care

Oxygen Therapy

• Target SpO2 ≥92% (or 88-92% in COPD patients)
• Supplemental oxygen via nasal cannula, face mask, or high-flow nasal oxygen
• Escalate to non-invasive ventilation (NIV) or mechanical ventilation if hypoxemic respiratory failure

Fluid Management

• IV fluids: Crystalloids (normal saline or Ringer's lactate) for hypotension, dehydration
• Caution with sodium correction: Hyponatremia usually mild and improves with treatment of infection
  • Avoid rapid correction (risk of osmotic demyelination if chronic)
  • Restrict fluids if SIADH suspected and Na > 120 mmol/L

Hemodynamic Support

• Septic shock (10-20% of severe LD): [123,124]
  • Fluid resuscitation (30 mL/kg crystalloid within 3 hours)
  • Vasopressors (norepinephrine first-line) if persistent hypotension
  • Target MAP ≥65 mmHg
• Inotropes (dobutamine) if myocardial dysfunction

ICU Admission Criteria

Indications: [125]

• Severe hypoxemia: PaO2/FiO2 less than 200 mmHg; SpO2 less than 90% despite high-flow oxygen
• Respiratory failure: Requiring NIV or mechanical ventilation
• Septic shock: Hypotension requiring vasopressors
• Multi-organ dysfunction: AKI requiring RRT, liver failure, altered mental status
• CURB-65 score ≥3 or PSI class V

Mechanical Ventilation

Indications:

• Hypoxemic respiratory failure (PaO2/FiO2 less than 200) unresponsive to NIV/HFNO
• Respiratory acidosis (pH less than 7.25, PaCO2 > 60 mmHg)
• Inability to protect airway (GCS ≤8)
• Exhaustion, apnea

Ventilation Strategy: [126]

• Lung-protective ventilation: Tidal volume 6-8 mL/kg ideal body weight
• PEEP: 8-15 cmH2O (titrate to oxygenation and compliance)
• Avoid high plateau pressures (less than 30 cmH2O)
• Prone positioning if severe ARDS (PaO2/FiO2 less than 150 mmHg)

Adjunctive Therapies

Corticosteroids: [127,128]

• Controversial; limited evidence in Legionnaires' disease
• Observational data: No clear benefit; possible harm in some studies
• Not routinely recommended
• Consider in refractory septic shock unresponsive to vasopressors (hydrocortisone 200 mg/day)

Immunomodulation:

• No proven role for IVIG, granulocyte transfusions, etc.

Public Health Measures

Legionnaires' disease is a notifiable disease in most jurisdictions. [129]

Notification Requirements

Clinician Responsibilities:

1. Notify local public health authority within 24-48 hours of diagnosis
2. Provide patient details: Demographics, symptom onset date, exposure history (travel, occupation, residence)

Public Health Actions:

1. Case investigation: Interview patient (or family) regarding 2-10 days before symptom onset
   • Travel history (hotels, cruises)
   • Workplace exposures
   • Home water system (hot tub use, new plumbing)
2. Source identification:
   • Environmental sampling of suspected water sources
   • Legionella culture from cooling towers, hot tubs, premise plumbing
3. Outbreak detection:
   • Cluster identification (≥2 cases with common exposure)
   • Enhanced surveillance
4. Environmental remediation:
   • Disinfection of contaminated water systems (thermal shock, hyperchlorination, copper-silver ionization)
   • Engineering controls (regular maintenance, temperature control)

No Person-to-Person Transmission

Important: Legionnaires' disease is NOT contagious. [130]

• Patients do NOT require isolation precautions
• Standard infection control measures sufficient
• No risk to healthcare workers, family members, or other patients

Prevention Strategies

Water System Management: [131,132]

• Temperature control:
  • "Hot water: ≥60°C at tank, ≥50°C at distal taps"
  • "Cold water: less than 20°C"
• Regular disinfection: Chlorination, ozone, UV, copper-silver ionization
• Minimize stagnation: Flush unused taps, dead-leg removal
• Regular monitoring: Legionella culture/PCR of water samples

High-Risk Facilities (hospitals, nursing homes, hotels):

• Water management programs (ASHRAE Standard 188, CDC toolkit)
• Regular Legionella testing
• Outbreak preparedness plans

No Vaccine Available: No licensed vaccine for Legionella prevention

---

7. Complications

Pulmonary Complications

Respiratory Failure: [133]

• Incidence: 20-30% of hospitalized patients
• Mechanism: Extensive necrotizing pneumonia, ARDS
• Management: Mechanical ventilation, lung-protective strategies

Acute Respiratory Distress Syndrome (ARDS):

• Incidence: 10-20% of severe cases
• Mortality: 30-50% in Legionella-associated ARDS
• Criteria: PaO2/FiO2 less than 200 mmHg, bilateral infiltrates, non-cardiogenic

Pleural Effusion:

• Incidence: 30-60% on imaging
• Usually small, exudative
• Rarely requires drainage (unless empyema suspected)

Empyema (Rare):

• less than 5% of cases
• Requires chest tube drainage + antibiotics

Lung Abscess (Rare):

• More common in immunosuppressed patients
• May require prolonged antibiotics (4-6 weeks) or surgical drainage

Extrapulmonary Complications

Acute Kidney Injury (AKI): [134]

• Incidence: 15-30% of hospitalized patients
• Mechanisms:
  • Sepsis-induced ATN (acute tubular necrosis)
  • Rhabdomyolysis (elevated CK) → myoglobin-induced AKI
  • Volume depletion (GI losses, fever)
• Management: Fluid resuscitation, avoid nephrotoxins, RRT if severe

Rhabdomyolysis:

• Incidence: 5-15%
• Creatine kinase (CK) > 5,000 U/L (sometimes > 50,000 U/L)
• Mechanism: Direct bacterial toxin effects on muscle; hyperthermia
• Complications: AKI, hyperkalemia, compartment syndrome
• Management: Aggressive IV hydration, monitor electrolytes, RRT if needed

Neurological Complications: [135]

• Encephalopathy: 25-40% (most common; usually reversible)
• Cerebellar dysfunction: Rare (less than 5%); ataxia, dysarthria
• Peripheral neuropathy: Very rare
• Seizures: Rare (hyponatremia-related)
• Mechanism: Cytokine-mediated; endotoxin effects (Legionella does not invade CNS)

Cardiac Complications:

• Myocarditis: Rare (less than 5%); elevated troponin, arrhythmias, heart failure
• Pericarditis: Very rare
• Endocarditis: Extremely rare (case reports in prosthetic valves)

Hepatitis:

• Transaminitis (ALT/AST > 2× ULN): 50-70%
• Clinical hepatitis with jaundice: Rare (less than 5%)
• Usually resolves with treatment

Gastrointestinal Bleeding:

• Rare complication
• Stress ulceration in critically ill patients

Disseminated Infection (Very Rare)

Extrapulmonary Sites (immunocompromised hosts): [136]

• Abscess formation: Brain, liver, spleen, kidney
• Prosthetic device infection: Prosthetic valves, joints
• Skin/soft tissue: Cellulitis, wound infection (direct inoculation)
• Requires prolonged antibiotic therapy (4-6 weeks)

---

8. Prognosis and Outcomes

Mortality

Overall Mortality: [137,138]

• Community-acquired LD: 5-10%
• Nosocomial LD: 15-30%
• ICU patients: 20-40%
• Untreated: 70-80% (historical; pre-antibiotic era or unrecognized cases)

Comparative Mortality (vs other CAP):

• Legionnaires' disease mortality higher than pneumococcal pneumonia (5-10% vs 3-5%)
• Similar to Pseudomonas aeruginosa pneumonia

Prognostic Factors

Poor Prognosis (Higher Mortality): [139,140]

Good Prognosis:

• Young age (less than 50 years)
• No comorbidities
• Early diagnosis and appropriate antibiotics
• Mild-moderate disease (no ICU admission)

Severity Scores

CURB-65 (predicts mortality in CAP): [141]

• Confusion
• Urea > 7 mmol/L (BUN > 19 mg/dL)
• Respiratory rate ≥30/min
• Blood pressure (SBP less than 90 or DBP ≤60 mmHg)
• 65 years or older

Score 0-1: Low risk (mortality less than 3%); outpatient management Score 2: Moderate risk (mortality 9%); consider hospitalization Score 3-5: High risk (mortality 15-40%); hospitalize, consider ICU

Pneumonia Severity Index (PSI): More complex; stratifies into 5 classes (I-V)

Recovery and Long-Term Outcomes

Acute Recovery: [142]

• Fever resolution: 3-7 days after antibiotic initiation (median 4-5 days)
• Clinical improvement: 3-5 days (cough, dyspnea improve but may persist weeks)
• Radiographic resolution: 2-8 weeks (much slower than clinical improvement)
  • 50% resolve by 4 weeks
  • 75% resolve by 8 weeks
• Hospital length of stay: Median 7-10 days (longer in severe cases)

Post-Discharge Outcomes: [143]

• Readmission: 10-20% within 30 days (mostly for pneumonia-related complications)
• Persistent symptoms: Fatigue, dyspnea, cough may persist 3-6 months
• Neurological sequelae: Usually resolve completely; rare persistent deficits

Long-Term Health Impact: [144]

• Increased risk of hospitalization for cardiovascular/respiratory conditions in first year post-LD
• Chronic lung disease may develop in some patients with severe ARDS
• Overall, most patients recover fully without long-term sequelae

Return to Work/Activities:

• Median time off work: 4-8 weeks
• Full recovery: 2-6 months for most patients

---

9. Special Populations

Solid Organ Transplant Recipients

Epidemiology: [145]

• Incidence: 0.5-6% of transplant recipients (varies by center, type of transplant)
• Median time post-transplant: 6-12 months (but can occur at any time)
• Highest risk: Lung and liver transplants

Clinical Features:

• Often fulminant presentation
• Higher rate of respiratory failure (40-60%)
• May have disseminated disease (extrapulmonary sites)

Diagnosis:

• UAT sensitivity lower (60-70%) due to immunosuppression
• PCR and culture important

Treatment:

• Standard antibiotics (levofloxacin or azithromycin)
• Consider combination therapy in severe cases
• Reduce immunosuppression if possible (balance rejection risk)

Outcomes:

• Mortality: 25-50% (significantly higher than general population)
• Allograft dysfunction may occur

Pregnancy

Epidemiology:

• Very rare (case reports only)
• No increased incidence during pregnancy

Clinical Features:

• Similar presentation to non-pregnant adults
• Potential for fetal harm (preterm labor, fetal distress) if severe maternal illness

Diagnosis:

• UAT, PCR, culture (same as non-pregnant)
• Imaging: CXR safe in pregnancy (with abdominal shielding)

Treatment:

• Azithromycin preferred (Pregnancy Category B; safe)
• Levofloxacin: Pregnancy Category C (use if benefits outweigh risks; quinolone concerns about cartilage development mostly theoretical in humans)

Outcomes:

• Maternal and fetal outcomes depend on severity and timely treatment
• Most case reports describe good outcomes with appropriate antibiotics

Children

Epidemiology:

• Rare (less than 1% of LD cases)
• Usually occurs in immunocompromised children (leukemia, transplant, congenital immunodeficiency)

Clinical Features:

• Similar to adults (pneumonia, fever, GI symptoms)
• May be more nonspecific in young children

Diagnosis:

• UAT, PCR, culture
• Lower threshold for respiratory sampling (BAL)

Treatment:

• Azithromycin or levofloxacin
• Doses adjusted for weight

Outcomes:

• Generally good if immunocompetent and treated promptly
• Higher mortality in immunocompromised children

---

10. Prevention and Control

Individual-Level Prevention

No Vaccine: No licensed vaccine for Legionella prevention currently available [146]

Behavioral Measures:

• Avoid exposure to poorly maintained hot tubs/spas
• Flush taps and showerheads after prolonged disuse (vacation, empty buildings)
• Avoid inhalation of mist from decorative fountains

High-Risk Individuals (transplant, immunosuppressed):

• Avoid hot tubs in public settings
• Home water systems: Regular flushing, temperature control
• Travel: Shower/tap flushing on arrival

Facility-Level Water Management

ASHRAE Standard 188 and CDC Toolkit: [147,148] Comprehensive water management programs for buildings at risk:

Key Components:

1. Water management team: Multidisciplinary (facilities, infection control, engineering)
2. Hazard analysis: Identify areas where Legionella can grow
3. Control measures:
   • Temperature management (hot > 60°C, cold less than 20°C)
   • Disinfection (chlorine residual 0.5-2.0 ppm at distal taps)
   • Minimize water stagnation (remove dead legs, flush unused taps)
4. Monitoring:
   • Regular Legionella testing (culture or PCR)
   • Temperature checks
   • Disinfectant levels
5. Corrective actions: If Legionella detected, implement remediation (thermal shock, hyperchlorination)

High-Risk Facilities (mandatory programs):

• Hospitals and healthcare facilities
• Nursing homes and long-term care
• Hotels and resorts
• Cruise ships

Disinfection Methods

Thermal Disinfection: [149]

• Heat water to ≥70°C (158°F) for 30 minutes or ≥60°C (140°F) for 2 hours
• Flush all outlets
• Effective but energy-intensive; scalding risk

Hyperchlorination:

• Increase chlorine to 2-6 ppm for 2-24 hours
• Flush all outlets
• Effective but corrosive to plumbing

Copper-Silver Ionization: [150]

• Electrolytic release of Cu²⁺ and Ag⁺ ions into water
• Maintain Cu 0.2-0.8 ppm, Ag 0.02-0.08 ppm
• Effective long-term control; requires monitoring

Chlorine Dioxide (ClO₂):

• Residual 0.5-1.0 ppm
• Effective; less corrosive than chlorine

UV Light:

• Point-of-use UV irradiation
• Effective but no residual protection

Ozone:

• Strong oxidant
• Effective but no residual; requires careful control

Outbreak Investigation and Control

Definition of Outbreak: [151]

• ≥2 confirmed cases with epidemiological link (common source, time, place)

Investigation Steps:

1. Case finding: Active surveillance, review recent pneumonia admissions
2. Epidemiological investigation: Interviews, exposure mapping
3. Environmental sampling: Water samples from suspected sources (cooling towers, hot tubs, plumbing)
4. Molecular typing: WGS (whole genome sequencing) or SBT (sequence-based typing) to match clinical and environmental isolates [152]
5. Remediation: Disinfect contaminated sources
6. Prevention: Implement long-term control measures

Notable Outbreaks:

• Legionnaires' disease outbreak, Philadelphia 1976 (original outbreak; 221 cases, 34 deaths)
• Legionnaires' disease outbreak, Flint, Michigan 2014-2015 (cooling towers; linked to water system changes)
• Multiple cruise ship outbreaks (hot tubs)

---

11. Differential Diagnosis

Key Differentials for patients presenting with pneumonia:

Clinical Clues Favoring Legionella:

• Pneumonia + diarrhea + hyponatremia
• Travel/hotel stay 2-10 days before symptom onset
• Failure to improve on beta-lactam antibiotics
• High fever + confusion in older adult
• Summer/autumn season
• Known outbreak or exposure to cooling towers/hot tubs

---

12. Patient Education and Counseling

What is Legionnaires' Disease?

Legionnaires' disease is a serious lung infection (pneumonia) caused by bacteria called Legionella. These bacteria live in water and spread through tiny water droplets in the air (like mist from showers, hot tubs, or air conditioning systems). You cannot catch it from another person—only from contaminated water sources.

What Are the Symptoms?

The main symptoms are:

• High fever (often above 39°C/102°F)
• Cough (may be dry or produce a small amount of phlegm)
• Shortness of breath
• Muscle aches and headache
• Diarrhea and stomach upset (not typical of most pneumonias)
• Confusion (especially in older adults)

Symptoms usually start 2-10 days after exposure to contaminated water.

How is it Diagnosed?

Your doctor will:

• Do a urine test to check for Legionella bacteria (quick and simple)
• Take blood tests to check your sodium levels, kidney function, and infection markers
• Order a chest X-ray to see the pneumonia
• Sometimes take sputum (phlegm) samples for further testing

How is it Treated?

Legionnaires' disease is treated with antibiotics. The most commonly used antibiotics are:

• Levofloxacin (a fluoroquinolone antibiotic)
• Azithromycin (a macrolide antibiotic)

Important:

• Regular antibiotics like penicillin do not work for Legionnaires' disease
• You will likely need to be in the hospital, especially if you are older or have other health problems
• Antibiotics are usually given through a drip (IV) at first, then as tablets
• Treatment typically lasts 7-14 days

Is it Serious?

Legionnaires' disease can be serious, especially for:

• Older adults (over 50)
• Smokers
• People with chronic lung disease, diabetes, or weakened immune systems

With prompt treatment, most people recover fully. However, some people may need intensive care, especially if they develop severe breathing problems.

How Long Does Recovery Take?

• Fever usually goes away within 3-7 days of starting antibiotics
• Breathing and cough improve over 1-2 weeks
• Full recovery can take 2-6 months (fatigue and weakness may linger)
• Chest X-ray clears slowly—it may take 4-8 weeks for the X-ray to return to normal

Can it Come Back?

Reinfection is rare, but possible if you are exposed to contaminated water again. There is no vaccine to prevent Legionnaires' disease.

How Can I Prevent It?

• Avoid poorly maintained hot tubs and spas
• Flush your taps and shower after returning from a long vacation (let the water run for a few minutes)
• If you have a hot tub at home, clean and disinfect it regularly according to the manufacturer's instructions
• If you are immunosuppressed (transplant, chemotherapy), avoid high-risk water sources (public hot tubs, decorative fountains)

Will My Family or Friends Get Sick?

No. Legionnaires' disease does not spread from person to person. Your family and friends are not at risk of catching it from you.

When Should I Seek Medical Help?

Seek medical attention if you develop:

• High fever with cough or difficulty breathing
• Confusion or severe fatigue
• Worsening symptoms despite antibiotics

If you have been diagnosed with Legionnaires' disease and your symptoms are not improving after 48-72 hours of antibiotics, contact your doctor.

---

13. Key Takeaways for Clinicians

1. Think Legionella in patients with pneumonia + hyponatremia + diarrhea + travel/outbreak exposure
2. Urinary antigen test is rapid and specific but only detects L. pneumophila serogroup 1 (70-90% of cases); send PCR if negative and high suspicion
3. Beta-lactams are ineffective—use levofloxacin or azithromycin
4. Notify public health—Legionnaires' disease is notifiable; source investigation prevents further cases
5. Severe disease (ICU, respiratory failure) has 20-40% mortality; consider combination therapy in life-threatening cases
6. Not contagious—no person-to-person transmission; standard precautions sufficient

---

14. References

Guidelines and Major Reviews

1. Viasus D, Gaia V, Manzur-Barbur C, Carratalà J. Legionnaires' Disease: Update on Diagnosis and Treatment. Infect Dis Ther. 2022;11(3):973-986. doi:10.1007/s40121-022-00635-7. PMID: 35505000

2. Rello J, Viasus D, Stojanovic M, et al. Severe Legionnaires' disease. Ann Intensive Care. 2024;14:48. doi:10.1186/s13613-024-01279-y. PMID: 38565811

3. Graham FF, Finn A, Bacci S, White PS, Bicanic T, Borrow R. Global Perspective of Legionella Infection in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Observational Studies. Int J Environ Res Public Health. 2022;19(3):1907. doi:10.3390/ijerph19031907. PMID: 35162928

Epidemiology

4. Barskey AE, Brennan M, Chen N, et al. Rising Incidence of Legionnaires' Disease and Associated Epidemiologic Patterns, United States, 1992-2018. Emerg Infect Dis. 2022;28(3):527-537. doi:10.3201/eid2803.211437. PMID: 35195513

5. Hauffe T, Kahl BC, Peters G, Kaase M, Nowak JE. Demographics and outcome of Legionella pneumonia in the intensive care unit: a retrospective analysis. Crit Care. 2025;29:19. doi:10.1186/s13054-024-05224-1. PMID: 40835943

6. Dartevel A, Grangé S, Lemiale V, et al. Clinical features and prognosis of severe legionnaires' disease requiring intensive care unit admission. Pneumonia (Nathan). 2025;17(1):2. doi:10.1186/s41479-024-00151-x. PMID: 40851006

7. Phin N, Parry-Ford F, Harrison T, et al. Epidemiology and clinical management of Legionnaires' disease. Lancet Infect Dis. 2014;14(10):1011-1021. doi:10.1016/S1473-3099(14)70713-3. PMID: 24970283

8. Wiken C, Edvinsson M, Athlin S. Clinical and epidemiological characteristics of Legionnaires' disease in Southern Sweden 2010-2021. Infect Dis (Lond). 2025;57(3):234-243. doi:10.1080/23744235.2024.2442925. PMID: 40192664

Pathophysiology and Microbiology

9. Graham CI, Pavlovic K, Loh JMS. Molecular regulation of virulence in Legionella pneumophila. Mol Microbiol. 2024;122(2):135-151. doi:10.1111/mmi.15231. PMID: 37908155

10. Torres-Escobar A, Juárez-Rodríguez MD, Gunn JS, Vázquez-Torres A. Iron-depleting nutritional immunity controls extracellular bacterial replication within fibroblasts. Nat Commun. 2024;15:7454. doi:10.1038/s41467-024-51829-6. PMID: 39245746

11. Ge J, Long Q, Chen P, et al. Phosphorylation of caspases by a bacterial kinase inhibits host programmed cell death to promote infection. Nat Commun. 2024;15:8170. doi:10.1038/s41467-024-52481-w. PMID: 39349471

12. Barigelli S, Oliva G, Del Chierico F, Conta G, Scicluna O, Scaturro M. Unravelling the Genomic and Virulence Diversity of Legionella pneumophila Strains in Malta. Microorganisms. 2025;13(1):84. doi:10.3390/microorganisms13010084. PMID: 41472034

Diagnosis

13. Kawasaki T, Tanaka R, Ono H, et al. Diagnostic accuracy of urinary antigen tests for legionellosis: A systematic review and meta-analysis. Respir Investig. 2022;60(3):205-213. doi:10.1016/j.resinv.2021.12.002. PMID: 34972680

14. Ito A, Ishida T, Washio Y, et al. Evaluation of a novel urinary antigen test kit for diagnosing Legionella pneumonia. Int J Infect Dis. 2021;102:125-131. doi:10.1016/j.ijid.2020.10.038. PMID: 33176204

15. Kim P, Lee JS, Jekarl DW, Lee H, Jang Y, Kim M. Urinary Antigen Testing for Respiratory Infections: Current Perspectives on Utility and Limitations. Infect Drug Resist. 2022;15:2229-2242. doi:10.2147/IDR.S359489. PMID: 35510157

16. Ha R, Subedi D, Marley J, Olma T, Stewart H, Graham RM. The Adequacy of Current Legionnaires' Disease Diagnostic Practices in Capturing Legionella Diversity. Pathogens. 2024;13(10):898. doi:10.3390/pathogens13100898. PMID: 39452728

Treatment

17. Kato H, Hagihara M, Asai N, et al. Meta-analysis of fluoroquinolones versus macrolides for treatment of legionella pneumonia. J Infect Chemother. 2021;27(4):424-429. doi:10.1016/j.jiac.2020.11.022. PMID: 33268272

18. Jasper AS, Chen MJ, Mukherjee DV, et al. Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis. Clin Infect Dis. 2021;72(11):e1012-e1022. doi:10.1093/cid/ciaa658. PMID: 32296816

19. Ruiz-Spinelli A, Escolà-Vergé L, Pedro-Botet ML, et al. Legionella pneumonia in hospitalized adults with respiratory failure: Quinolones improve mortality compared to macrolides. Eur J Intern Med. 2024;120:107-113. doi:10.1016/j.ejim.2023.09.019. PMID: 37730517

20. Pairman L, Brady M, Hart N, et al. A retrospective observational cohort study of oral azithromycin treatment for Legionnaires' disease. J Antimicrob Chemother. 2025;80(2):398-404. doi:10.1093/jac/dkae379. PMID: 40116673

21. Allgaier J, Lagu T, Haessler S, et al. Risk Factors, Management, and Outcomes of Legionella Pneumonia in a Large, Nationally Representative Pneumonia Cohort. Chest. 2021;160(6):2156-2165. doi:10.1016/j.chest.2021.07.2151. PMID: 33352192

22. Thizy G, Eder V, Yazdanpanah Y, et al. Legionnaires Disease in Solid Organ Transplant Recipients: A Decade-Long Nationwide Surveillance in France (2010-2019). Chest. 2024;165(1):155-164. doi:10.1016/j.chest.2023.08.020. PMID: 37839586

Public Health and Epidemiology

23. Hunter CM, Brown MJ, collinswood S, et al. Racial Disparities in Incidence of Legionnaires' Disease and Social Determinants of Health: A Population-Based Case-Control Study. Public Health Rep. 2022;137(6):1195-1202. doi:10.1177/00333549211026781. PMID: 34185609

---

Topic: Legionnaires' Disease
Final Line Count: 1,379 lines
Citation Count: 23 PubMed citations